MS Clinical Trial: Safety Study of FTY720

Application No:  NA_00023166

Principal Investigator: John (Jack) Ratchford

For more information please contact Regina Brock-Simmons at 443-287-6079 or via email at apalich2(at)jhmi(dot)edu.

This study is a double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis.

This research is being done to study the safety and effectiveness of the investigational drug fingolimod (FTY720) in people who have Primary Progressive Multiple Sclerosis (PPMS).  Participants in this study must be between the ages of 18 and 65 with a diagnosis of PPMS.  Symptoms must have been present for less than 10 years.

Request an Appointment

For more information about MS treatment options, request an appointment with our doctors.